Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.76), which may not compare to the analyst estimate of ($0.05). Revenue for the quarter came in at $204.55 million versus the consensus estimate of $207.56 million.

GUIDANCE:

Tandem Diabetes sees Q4 2022 revenue of $800-805 million, versus the consensus of $836.4 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.